(HALO) Halozyme Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(HALO) Halozyme Therapeutics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Halozyme Therapeutics, Inc. BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, and what that means for strategy and capital allocation. The content shown on this page is a real preview of the actual report, so you can review the format and sample analysis before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
ENHANZE platform licensing engine
Halozyme Therapeutics, Inc.'s ENHANZE platform is the core growth engine: rHuPH20 helps convert IV biologics to subcutaneous dosing, which can cut infusion time from hours to minutes. It runs through a broad partner base, including Roche, Johnson & Johnson, argenx, and Bristol Myers Squibb, and keeps adding value through new launches and label expansions. In 2025, that model stayed Halozyme Therapeutics, Inc.'s main royalty driver and the key reason the platform fits the Stars quadrant.
DARZALEX FASPRO royalties
DARZALEX FASPRO is Halozyme Therapeutics, Inc.’s largest royalty engine, with Johnson & Johnson reporting daratumumab sales above $10 billion in 2024. The subcutaneous brand leads SC oncology delivery and targets multiple myeloma and AL amyloidosis, making it a Halozyme cash cow in the BCG Matrix.
PHESGO royalty stream
PHESGO is a mature Star in Halozyme Therapeutics, Inc.'s BCG view because it combines pertuzumab and trastuzumab with hyaluronidase for HER2-positive breast cancer and keeps expanding subcutaneous use worldwide. Roche reported PHESGO sales of CHF 1.85 billion in 2024, showing strong commercial scale and long life. That broad use supports a durable royalty stream for Halozyme Therapeutics, Inc. and keeps cash flow visible.
VYVGART Hytrulo royalties
VYVGART Hytrulo royalties are a Star in Halozyme Therapeutics, Inc.’s BCG mix because they turn Argenx’s efgartigimod into a subcutaneous product, which supports faster use and wider access. The franchise now spans gMG and CIDP, two autoimmune neurology markets with clear growth runway. Adoption and geographic reach are still expanding, so royalty upside remains tied to volume growth.
- Subcutaneous delivery drives use
- Two growing indications: gMG, CIDP
- Expansion is still underway
OCREVUS ZUNOVO royalties
OCREVUS ZUNOVO is a Stars asset for Halozyme Therapeutics, Inc. because it brings subcutaneous ocrelizumab into a multiple sclerosis market affecting about 2.9 million people worldwide and about 1 million in the U.S. Its launch adds another high-volume ENHANZE royalty stream, tied to a proven anti-CD20 therapy with broad use. That makes it a key growth driver.
- Large, treated MS market
- Subcutaneous ocrelizumab launch
- High-volume ENHANZE royalties
- Scales with ongoing use
Halozyme’s ENHANZE Stars Keep Delivering Growth
Halozyme Therapeutics, Inc.’s Stars are the ENHANZE royalty set: DARZALEX FASPRO, PHESGO, VYVGART Hytrulo, and OCREVUS ZUNOVO. In 2024, Johnson & Johnson’s daratumumab sales topped $10 billion and Roche’s PHESGO sales reached CHF 1.85 billion, while VYVGART Hytrulo and OCREVUS ZUNOVO still had clear expansion runway.
| Asset | Key 2024 data |
|---|---|
| DARZALEX FASPRO | >$10B sales |
| PHESGO | CHF 1.85B sales |
What is included in the product
Detailed Word Document
Halozyme’s BCG matrix maps its drug-delivery portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
One-page Halozyme Therapeutics BCG Matrix that clarifies each business unit for quick, pain-free strategy reviews
Reference Sources
Provides a credible source trail for Halozyme Therapeutics, helping users verify claims quickly and make better-informed decisions.
Cash Cows
Hylenex recombinant
Hylenex recombinant is Halozyme Therapeutics, Inc.'s own recombinant hyaluronidase, used for fluid administration and injection dispersion. It is a mature franchise with stable demand, not a high-growth driver, so it fits the Cash Cows slot in the BCG Matrix. Its long market history and steady use support dependable cash flow rather than rapid expansion.
HYQVIA royalties
HYQVIA royalties fit Halozyme Therapeutics, Inc. as a Cash Cow: the therapy has been on market since 2014 and serves a durable immunodeficiency patient base, so royalty revenue is recurring while marketing spend stays low. In 2025, Halozyme still reported HYQVIA as an established royalty stream, supporting cash flow without heavy launch costs. That makes it a mature, low-growth but reliable contributor.
Legacy mature licensing fees
Halozyme Therapeutics, Inc. gets steady cash from legacy ENHANZE licensing fees tied to older partner deals, and those contracts need little added commercial support. That makes this a classic Cash Cow: low reinvestment, predictable royalties, and high margin cash flow. In 2025, Halozyme kept using this base to fund growth in newer programs while preserving earnings quality.
Established global immunology installs
Halozyme Therapeutics, Inc.'s global immunology installs are a cash cow because its ENHANZE-enabled subcutaneous products sit in chronic care paths, so patients keep using them and royalties recur. The base is broad, with more than 10 commercial partnered products and 500,000+ cumulative infusions in prior disclosures, which helps support steady cash flow even in a low-growth segment.
- Recurring use in chronic therapy
- Embedded in global immunology care
- Stable royalty-driven cash flow
Long-tail royalty income
Halozyme Therapeutics, Inc.'s long-tail royalty income still matters because older ENHANZE deals keep paying royalties and milestones, while revenue is spread across multiple licensees instead of one drug. That mix helps smooth cash generation across cycles, and by 2025 the company still had a broad partnered base supporting recurring royalty cash flow.
- Older assets still pay royalties.
- Multiple licensees reduce concentration.
- Cash flow stays steadier across cycles.
Halozyme’s Cash Cows Keep 2025 Cash Flow Steady
Halozyme Therapeutics, Inc.'s Cash Cows are Hylenex recombinant and legacy ENHANZE royalties: mature, low-growth, and still cash-generative in 2025.
HYQVIA royalties also stayed recurring, with a durable immunodeficiency base and low added sales spend.
Halozyme Therapeutics, Inc. had more than 10 commercial partnered products and 500,000+ cumulative infusions, which helped keep cash flow steady.
| Cash cow | Why it fits |
|---|---|
| Hylenex recombinant | Mature, stable demand |
| HYQVIA royalties | Recurring 2025 revenue |
Preview the Actual Deliverable
Halozyme Therapeutics, Inc. Reference Sources
This Halozyme Therapeutics, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo pages, no hidden changes—just the full, professionally formatted report. Download it instantly and use it for analysis, presentations, or strategic planning.
Dogs
RITUXAN HYCELA
RITUXAN HYCELA is a legacy oncology asset for Halozyme, built on rituximab and used in subcutaneous delivery. The product faces biosimilar pressure in rituximab, and the market has shown slower growth, so it is no longer a flagship driver for Halozyme. In Halozyme's 2025 mix, growth is led by newer partnered assets, not RITUXAN HYCELA.
MABTHERA SC
MABTHERA SC is a Dog in Halozyme Therapeutics, Inc.’s BCG view: it is the ex-U.S. rituximab SC franchise in a mature anti-CD20 market, so growth is limited and pricing power is weak. Compared with newer ENHANZE launches, its revenue mix is small and expansion is slower, which fits a low-growth, low-share profile. It adds cash flow, but it is not a major growth driver.
RITUXAN SC legacy use
RITUXAN SC is a legacy asset in a crowded rituximab market that has faced biosimilar pressure since 2017. Demand is softer as switch dynamics and lower-priced rivals cap growth, while Roche reported RITUXAN sales of about $1.1 billion in 2024, down sharply from peak years. That makes it a low-growth, low-share Dogs name in Halozyme Therapeutics, Inc.’s BCG matrix.
Small-volume mature oncology conversions
Older SC conversion products in hematology are the Dogs in Halozyme Therapeutics, Inc.’s BCG view: they still throw off residual cash, but momentum is far weaker than newer franchises and their market role is well below the company’s top assets. In 2025, Halozyme still leaned on ENHANZE royalty streams, but these legacy products look like low-growth holdovers, not growth engines.
- Residual cash flow, not growth
- Weaker than newer franchises
- Below top-asset market position
Inactive or dormant partner programs
Halozyme Therapeutics, Inc.’s inactive partner programs are legacy collaborations that no longer drive meaningful commercial revenue. They use little capital and require limited ongoing attention, but they also add almost no growth, so they sit in the BCG “dog” bucket. The value today comes from core ENHANZE partners, while these dormant deals mostly sit on the sidelines.
- Low capital use, low revenue
- No clear growth contribution
- Legacy value only, not a driver
Halozyme’s Dogs: Legacy Deals Under Pressure, ENHANZE Takes Focus
Halozyme Therapeutics, Inc.’s Dogs are legacy SC rituximab products and inactive partner deals that add cash but little growth. In 2025, the franchise stayed under pressure from biosimilars and slow anti-CD20 demand, so it fits a low-share, low-growth BCG slot. The focus is on ENHANZE royalties, not these holdovers.
| Dogs item | 2025 view | BCG fit |
|---|---|---|
| RITUXAN HYCELA | Legacy, pressured | Dog |
| MABTHERA SC | Small, mature | Dog |
| Inactive partners | Minimal revenue | Dog |
Question Marks
Tecentriq SC program
Tecentriq SC is a question mark: it targets a huge oncology pool, but it must win share from entrenched IV atezolizumab and rival PD-1/PD-L1 drugs. Roche reported Tecentriq sales of about CHF 3.9 billion in 2024, so the SC form could matter if it lifts convenience and site-of-care savings. For Halozyme, that is high upside, low current share.
Nivolumab SC program
Nivolumab SC sits in a blockbuster market: Opdivo has been a $9B+ annual franchise, so even modest conversion from IV could be meaningful for Halozyme Therapeutics, Inc. The key risk is uptake, because oncologists must switch from a proven IV routine to a newer SC option. Early share, not demand, is the main unknown.
ARGX-113 SC expansion
ARGX-113, the efgartigimod SC franchise, is a clear Question Mark because new autoimmune labels can widen the market fast, but share is still early. Vyvgart Hytrulo already moved beyond generalized myasthenia gravis, and the CIDP approval gave it a second large indication. Halozyme’s ENHANZE base has shown SC delivery can scale, but this asset still needs more real-world uptake to prove its profit pool.
ARGX-117 pipeline
ARGX-117 is a Question Mark in Halozyme Therapeutics, Inc.’s BCG view: it targets autoimmune disease, but it is still in development and has no sales base or proven share yet. That means the asset has upside if trials and launch go well, but it also carries high clinical and commercial risk. In BCG terms, it needs capital before it can become a cash generator.
- Autoimmune pipeline asset
- Pre-revenue, no market share
- High upside, high risk
- Needs funding to scale
BMS-986179 collaboration
BMS-986179 is an early-stage anti-CD73 antibody partnership for Halozyme Therapeutics, Inc., so it fits a question mark: high market upside, but no proven share yet. Oncology immunotherapy is still a huge field, with global cancer spending and checkpoint-style programs driving deal flow, but CD73 assets face high clinical and competitive risk before any clear payoff.
- Partnered, early-stage asset
- Large oncology immunotherapy market
- Share is not yet established
- High development risk remains
Halozyme’s Q Marks: Big Upside, Little Proof
Halozyme Therapeutics, Inc.’s question marks are early bets with large upside but little proven share yet. Tecentriq SC and Nivolumab SC sit in multibillion-franc and $9B+ oncology markets, while ARGX-117 and BMS-986179 are still pre-revenue. They need adoption or trial wins to move toward stars.
| Asset | Why Q mark |
|---|---|
| Tecentriq SC | CHF 3.9B 2024 base |
| Nivolumab SC | $9B+ franchise |
| ARGX-117 | Pre-revenue |
| BMS-986179 | Early-stage |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.